Illumina and ReaMetrix to Collaborate on Molecular Diagnostics and Market Development
Illumina, Inc. and ReaMetrix, Inc. announced the formation of a diagnostic collaboration under which the companies plan to co-develop molecular diagnostic panels for a range of disease areas. Under the terms of the agreement, ReaMetrix will gain non-exclusive rights to market the resulting panels to the country of India and its more than one billion inhabitants. Illumina will retain rights to market the tests outside of India.
Illumina will supply VeraCode(TM) technology and other reagents for the tests. ReaMetrix will develop, validate and market diagnostic panels based on Illumina's upcoming BeadXpress(TM) platform, scheduled for market introduction before the end of the calendar year.
ReaMetrix will drive market development activities from its operation in Bangalore, India. According to Bala Manian, Ph.D., ReaMetrix Chief Executive Officer, "India's rapidly emerging healthcare system presents a tremendous opportunity to leapfrog current diagnostics and chart a new path with innovative molecular and pharmacogenomic testing. Teaming up with Illumina and its BeadXpress diagnostic platform, we see a significant opportunity to drive the evolution toward the efficiencies inherent in targeted, personalized medicine. In targeting the wide-open Indian market, we will be creating products that will drive value the world over."
Most read news
Organizations
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/awportal/images/newsletter.png)
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
![Topic world Diagnostics](http://static.chemie.de//media/images/focuspage/fad88bce-b1d2-4521-90d9-208976e9430e.png)
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.